Effect of sildenafil citrate on prediabetic and diabetic albino rats treated with metformin
DOI:
https://doi.org/10.31878/ijcrpp.2021.51.02Keywords:
Diabetes Mellitus, DM, Sildenafil, MetforminAbstract
Diabetes Miletus (DM) is a global epidemic disease. It is estimated that there are already 415 million adults aged 20–79 years diabetics worldwide. Sildenafil citrate is a phosphodiesterase type 5 (PDE5) inhibitor, which increases cyclic guanosine monophosphate (cGMP) and metformin (MET) is a biguanide used for the treatment of type 2 diabetes which increases peripheral insulin sensitivity.
Aim: This study aims to assess the effect of sildenafil citrate and metformin on lipid profile and glycemic control in diabetic and prediabetic albino rats.
Materials and methods: Adult male albino rats are used and divided into nine groups each group consists of 10 rats, diabetes is induced by feeding a high-fat diet (HFD) for an initial period of 2 weeks followed by a single intraperitoneal injection of (35 mg/kg) Streptozotocin. Prediabetes is induced by feeding (HFD) and glucose in water for a period of 2 weeks. Sildenafil was given in a dose of (5 &10 mg/kg/day orally for 4 weeks), metformin was given in a dose of (50 &100 mg/kg/day orally for 4 weeks) using oral gavages to normal healthy rats, diabetic and prediabetic rats. Blood samples were collected after 4 weeks of treatment in all experimental groups.
Results: Combined administration of sildenafil and metformin on diabetic rats improving hyperglycemia, oxidative stress, and hyperlipidemia induced by streptozotocin than the administration of metformin or sildenafil alone.
Conclusion: Sildenafil has beneficial effects against some diabetic complications. The present study showed that sildenafil with metformin has beneficial effects against diabetic complications.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Ahmed Mohmed Taha, Haredy Hassan Haredy, Ahmed Ghareip, Ahmed El sayed Nour el-deen, Yasser M Ashour
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
The submitted papers are assumed to contain no proprietary material unprotected by patent or patent application; responsibility for technical content and for protection of proprietary material rests solely with the author(s) and their organizations and is not the responsibility of the journal. The main (first/corresponding) author is responsible for ensuring that the article has been seen and approved by all the other authors. It is the responsibility of the author to obtain all necessary copyright release permissions for the use of any copyrighted materials in the manuscript prior to the submission.
What are my rights as an author?
It is important to check the policy for the journal to which you are submitting or publishing to establish your rights as
Author. Journal's standard policies allow the following re-use rights:
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to obtain publishing rights without restrictions.
- You may do whatever you wish with the version of the article you submitted to the journal.
- Once the article has been accepted for publication, you may post the accepted version of the article on your own personal website, your department's website or the repository of your institution without any restrictions.
- You may not post the accepted version of the article in any repository other than those listed above (i.e. you may not deposit in the repository of another institution or a subject-matter repository) until 12 months after publication of the article in the journal.
- You may use the published article for your own teaching needs or to supply on an individual basis to research colleagues, provided that such supply is not for commercial purposes.
